EPIGENETIC THERAPIES TO DIFFERENTIATE AND ERADICATE LEUKAEMIA STEM CELLS
Grant number: 1146192 | Funding period: 2019 - 2021
Active
Abstract
Leukemia stem cells (LSC) are often resistant to conventional and targeted therapies and therefore serve as the seed for leukaemia relapse. The overall aim of this project is to use small molecule therapies to block the activity of a particular protein (LSD1) in LSC in order to differentiate them and expose a vulnerability to another epigenetic therapy called a BET inhibitor. Together, these epigenetic therapies will differentiate and eradicate LSC, leading to improved outcome in AML.